Physician profile
Molly E Schooley
NPI 1225332463
$104,809.11
in general payments reported to CMS, 2019-2025
49 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,747 · 2022: $34K · 2023: $19K · 2024: $16K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $16K · Travel and Lodging: $8,283 · Food and Beverage: $7,129 · Education: $50.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,098.13 |
| Consulting Fee | $15,758.75 |
| Travel and Lodging | $8,282.91 |
| Food and Beverage | $7,128.92 |
| Education | $50.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $72,906.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $26,379.74 | 2021-2025 | |
| Lilly USA, LLC | $683.97 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk As | $595.00 | 2024-2025 | |
| Amgen INC. | $390.90 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $363.98 | 2021-2025 | |
| Abbvie INC. | $315.69 | 2021-2025 | |
| Radius Health, INC. | $256.79 | 2021-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.94 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Aimmune Therapeutics, INC. | $255.66 | 2024 | |
| Merck Sharp & Dohme LLC | $233.20 | 2021-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Astellas Pharma US INC | $167.44 | 2021-2025 | Veozah, Myrbetriq |
| Insulet Corporation | $163.24 | 2024-2025 | Omnipod, Omnipod |
| Ascendis Pharma Endocrinology INC | $162.93 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $153.44 | 2021-2023 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $149.45 | 2021-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $120.13 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $119.98 | 2021-2024 | |
| Esperion Therapeutics, INC. | $114.69 | 2021-2025 | Nexletol |
| Medtronic, INC. | $101.99 | 2021-2024 | Minimed 780g |
| Corcept Therapeutics | $88.63 | 2024-2025 | Korlym |
| Dexcom, INC. | $87.03 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $65.73 | 2021-2022 | |
| Mannkind Corporation | $62.99 | 2025 | |
| Daiichi Sankyo INC. | $59.88 | 2024 | Injectafer |
| Kyowa Kirin, INC. | $53.61 | 2023-2024 | Crysvita |
| Glaxosmithkline, LLC. | $50.96 | 2023-2025 | Bexsero, Pediarix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.03 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $31.51 | 2024-2025 | Trintellix |
| Impel Pharmaceuticals INC. | $29.68 | 2022-2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $28.48 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $28.37 | 2022-2025 | Rexulti |
| Seqirus USA INC | $26.02 | 2025 | Flucelvax |
| Abbott Laboratories | $24.26 | 2021 | |
| Verona Pharma, INC. | $20.96 | 2025 | Ohtuvayre |
| Tonix Medicines, INC. | $19.89 | 2025 | Tonmya |
| Janssen Pharmaceuticals, INC | $19.11 | 2021 | |
| Madrigal Pharmaceuticals | $18.05 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $16.87 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.81 | 2025 | Camzyos |
| Tandem Diabetes Care, INC. | $15.62 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Nestle Healthcare Nutrition INC. | $15.46 | 2021 | |
| Zealand Pharma US, INC. | $15.07 | 2021 | |
| Organon LLC | $14.97 | 2023 | Nexplanon |
| Exact Sciences Corporation | $14.05 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $13.88 | 2023 | Yupelri |
| Antares Pharma, INC. | $12.39 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Schooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.